Cannabis Usage Trends: Daily Use, Demographics, and Consumption Patterns

Executive Summary

Daily marijuana use in the United States has surpassed daily tobacco use for the first time in recorded history, according to national survey data released in July 2026. The milestone reflects decades of shifting social attitudes, expanding state-level legalization, and declining cigarette consumption. Approximately 17.5 million Americans now report using cannabis daily or near-daily, compared to roughly 16.9 million daily tobacco smokers. This demographic shift carries profound implications for public health policy, workplace drug testing protocols, federal scheduling debates, and the multi-billion-dollar cannabis industry. The trend spans all age groups but concentrates most heavily among adults aged 26-49, with medical patients, recreational users, and microdosers all contributing to the surge. As cannabis normalization accelerates and tobacco use continues its five-decade decline, policymakers face urgent questions about impaired driving standards, youth prevention strategies, and the federal-state legal conflict that still classifies cannabis as a Schedule I controlled substance under the Controlled Substances Act.

Why This Matters

The crossover of cannabis past tobacco represents a generational public health transformation with stakes measured in billions of dollars, millions of patients, and fundamental questions about American drug policy. For the 38 states with legal medical programs and 24 states with adult-use markets, rising daily consumption validates the economic projections that drove legalization campaigns. The legal cannabis industry generated $33.6 billion in sales during 2025, according to industry analytics firm BDSA, with daily users accounting for an estimated 75-80% of total purchases. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings depend on this core consumer base for revenue stability. Public health officials confront new challenges. While cannabis lacks the cardiovascular and cancer risks associated with combustible tobacco, daily use raises concerns about cannabis use disorder, cognitive effects in developing brains, and mental health outcomes in vulnerable populations. The National Institute on Drug Abuse estimates that approximately 10% of cannabis users develop dependence, with rates climbing to 17% among those who start in adolescence. Employers face mounting pressure to revise drug testing policies. Traditional pre-employment and random screening programs designed for a prohibition era increasingly conflict with state-level protections for off-duty cannabis use. Major corporations including Amazon, Walmart, and CVS Health have eliminated pre-employment cannabis testing for many positions, recognizing that blanket prohibition shrinks available labor pools in tight job markets. Federal agencies operate in sustained contradiction. The Drug Enforcement Administration maintains cannabis in Schedule I of the Controlled Substances Act, defined as having "no currently accepted medical use" and "high potential for abuse," even as the Department of Health and Human Services recommended rescheduling to Schedule III in August 2023. The disconnect between federal prohibition and state-level normalization creates compliance nightmares for banks, insurers, and interstate commerce.

Background and History: From Reefer Madness to Daily Normalization

The path from cannabis prohibition to daily use exceeding tobacco spans nearly a century of policy reversals, cultural shifts, and accumulating scientific evidence.

The Prohibition Era: 1937-1970

The Marihuana Tax Act of 1937 effectively criminalized cannabis at the federal level, driven by Federal Bureau of Narcotics Commissioner Harry Anslinger's campaign linking cannabis to violence and moral decay. The act imposed prohibitive taxes and registration requirements on cannabis transactions. For three decades, cannabis remained legally available only through narrow medical channels, with use concentrated in jazz subcultures and marginalized communities. The Controlled Substances Act of 1970, signed by President Richard Nixon, formalized prohibition by placing cannabis in Schedule I alongside heroin and LSD. The classification required findings that cannabis had high abuse potential, no accepted medical use, and lacked safety for use under medical supervision. Nixon's appointment of the Shafer Commission in 1972 produced recommendations to decriminalize personal possession, which the administration ignored.

Decriminalization Experiments: 1973-1996

Oregon became the first state to decriminalize small-amount possession in 1973, reducing penalties to civil violations. Ten additional states followed by 1978, including California, Colorado, and New York. These early reforms reduced arrest rates but did not establish legal supply channels. California's Proposition 215, passed in November 1996, created the first state-legal medical cannabis program. The Compassionate Use Act allowed patients with physician recommendations to possess and cultivate cannabis for conditions including cancer, AIDS, glaucoma, and chronic pain. The law provided no regulatory framework for production or distribution, leading to a gray-market patchwork of dispensaries and collectives.

Medical Expansion: 1998-2012

Alaska, Oregon, and Washington approved medical programs in 1998. By 2012, 18 states plus the District of Columbia had enacted medical cannabis laws, though implementation varied dramatically. Some states like Colorado and Michigan developed licensed dispensary systems; others including New Jersey and Arizona imposed strict qualifying conditions and limited supply channels. Federal enforcement remained aggressive. The Supreme Court ruled in Gonzales v. Raich (2005) that federal prohibition authority under the Commerce Clause extended to intrastate medical cannabis cultivation. DEA raids on state-compliant dispensaries continued through the George W. Bush administration. The Obama administration issued the Ogden Memorandum in 2009, directing federal prosecutors to deprioritize cases involving individuals in "clear and unambiguous compliance" with state medical laws.

Adult-Use Breakthrough: 2012-2020

Colorado and Washington approved adult-use legalization via ballot initiatives in November 2012, with sales commencing in January 2014 and July 2014 respectively. Both states established comprehensive regulatory frameworks including cultivation licensing, product testing, packaging requirements, and retail taxation. Alaska, Oregon, and the District of Columbia legalized in 2014. California, Massachusetts, Maine, and Nevada followed in 2016. Illinois became the first state to legalize through legislative action rather than ballot initiative in 2019. By January 2020, 11 states permitted adult-use sales. The 2018 Farm Bill removed hemp—defined as cannabis containing less than 0.3% delta-9 THC—from Schedule I, legalizing CBD products derived from hemp. The distinction created a booming but poorly regulated market for hemp-derived cannabinoids including delta-8 THC and THCA.

Pandemic Acceleration: 2020-2023

Cannabis retailers were designated essential businesses in most legal states during COVID-19 lockdowns. Sales surged 46% in 2020 as consumers stockpiled products and new users experimented during isolation. Delivery and curbside pickup options expanded rapidly. New Jersey, New York, Virginia, New Mexico, and Connecticut legalized adult use between 2020-2021. Montana, South Dakota, and Arizona approved legalization via 2020 ballot measures, though South Dakota's measure faced legal challenges. By mid-2023, 24 states representing 54% of the U.S. population had legal adult-use markets.

Federal Rescheduling Process: 2023-Present

President Joe Biden directed HHS and the Department of Justice to review cannabis scheduling in October 2022. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on findings that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking in May 2024, initiating the formal rescheduling process. The proposal triggered a 60-day public comment period and an administrative law judge hearing scheduled for December 2024. As of July 2026, the rescheduling remains pending, with industry observers anticipating final action in late 2026 or early 2027.

Key Players in the Usage Trend Shift

National Institute on Drug Abuse

NIDA conducts the Monitoring the Future survey tracking adolescent drug use and the National Survey on Drug Use and Health measuring adult consumption patterns. The agency's longitudinal data provides the empirical foundation for usage trend analysis. NIDA Director Dr. Nora Volkow has emphasized the need for research on daily use patterns, cognitive effects, and cannabis use disorder treatment.

RAND Corporation

RAND researchers published foundational studies on cannabis consumption patterns, finding that daily and near-daily users account for the majority of total cannabis consumed despite representing a minority of users. The research informed regulatory approaches to taxation and public health messaging.

Multi-State Operators

Curaleaf, Trulieve, Green Thumb Industries, Verano Holdings, and Cresco Labs operate hundreds of dispensaries across multiple states. These MSOs track purchasing patterns through loyalty programs and point-of-sale data, providing granular insights into daily user behavior. Daily consumers represent the most valuable customer segment, with average annual spending exceeding $2,500 per person.

NORML

The National Organization for the Reform of Marijuana Laws has advocated for legalization since 1970. NORML Deputy Director Paul Armentano has testified before state legislatures and federal committees on usage trends, emphasizing that increased daily use reflects substitution away from alcohol and tobacco rather than net increases in intoxicant consumption.

Smart Approaches to Marijuana

SAM, founded by former U.S. Representative Patrick Kennedy and Kevin Sabet, opposes legalization and commercialization. The organization cites rising daily use as evidence that legalization increases problematic consumption, particularly among youth and vulnerable populations. SAM advocates for decriminalization without commercialization.

Legal and Regulatory Framework

Cannabis usage exists in a complex legal matrix where federal prohibition collides with state-level legalization, creating inconsistent protections and enforcement priorities. The Controlled Substances Act, 21 U.S.C. § 801 et seq., classifies cannabis as a Schedule I controlled substance under 21 U.S.C. § 812(c). Schedule I designation requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Possession, cultivation, and distribution remain federal felonies under 21 U.S.C. § 841, with penalties ranging from one year to life imprisonment depending on quantity. State medical cannabis laws create affirmative defenses to state prosecution but provide no protection against federal charges. The Rohrabacher-Farr Amendment, renewed annually in federal appropriations bills since 2014, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. The provision does not protect recreational programs or individual users from federal prosecution. The Cole Memorandum, issued by Deputy Attorney General James Cole in August 2013, established eight enforcement priorities for federal prosecutors in legal states: preventing distribution to minors, preventing revenue to criminal enterprises, preventing diversion to prohibition states, preventing state-authorized activity from serving as cover for trafficking, preventing violence and firearms in cultivation and distribution, preventing drugged driving, preventing cultivation on public lands, and preventing possession on federal property. Attorney General Jeff Sessions rescinded the Cole Memoraneum in January 2018, though federal prosecution of state-compliant operators remained rare. Employment law varies dramatically by state. Some states including Nevada, New Jersey, New York, and Connecticut prohibit employment discrimination based on off-duty cannabis use or positive drug tests absent evidence of workplace impairment. Other states provide no employment protections, allowing termination for any cannabis use regardless of medical status. Federal employees and contractors remain subject to zero-tolerance policies under the Drug-Free Workplace Act of 1988. The Farm Bill of 2018, 7 U.S.C. § 1639o, removed hemp from the Controlled Substances Act, defining hemp as cannabis containing not more than 0.3% delta-9 THC on a dry weight basis. The distinction created a legal market for CBD and hemp-derived cannabinoids, though the Food and Drug Administration maintains that adding CBD to food products or marketing CBD as a dietary supplement violates the Federal Food, Drug, and Cosmetic Act.

State-by-State Breakdown of Usage Patterns

Daily cannabis use concentrates most heavily in states with mature adult-use markets and robust medical programs, though usage has increased across all regions.

California

California leads the nation in total cannabis consumers with an estimated 6.8 million past-month users as of 2025. Daily users comprise approximately 28% of past-month consumers. The state's Proposition 64, approved in 2016, legalized adult use for those 21 and older with possession limits of one ounce of flower and eight grams of concentrate. Medical patients may possess up to eight ounces. Daily use increased 34% between 2019 and 2025, driven by expanded retail access and declining prices.

Colorado

Colorado's mature market, operational since 2014, shows the highest daily use prevalence at 31% of past-month users. The state permits possession of one ounce for adult use and two ounces for medical patients. Daily users skew toward medical cardholders seeking relief from chronic pain, PTSD, and anxiety. Average daily consumption among regular users is 1.2 grams of flower or equivalent.

New York

New York legalized adult use in March 2021, with licensed retail sales commencing in December 2022. Daily use increased 41% between 2021 and 2025 as legal access expanded. The state permits possession of three ounces of flower and 24 grams of concentrate. New York prohibits employment discrimination based on off-duty cannabis use under Labor Law § 201-d, providing stronger worker protections than most states.

Florida

Florida operates one of the nation's largest medical-only programs with over 850,000 active patients as of July 2026. Daily use is concentrated among medical cardholders, who may purchase up to 2.5 ounces of flower every 35 days plus unlimited smokeless products. A ballot initiative to legalize adult use, Amendment 3, is scheduled for November 2026. Polling shows 64% support, above the 60% threshold required for constitutional amendments.

Texas

Texas maintains one of the nation's most restrictive programs, limiting medical cannabis to low-THC products (0.5% THC or less) for a narrow list of qualifying conditions. Daily use remains lowest in prohibition states like Texas, though delta-8 THC and THCA products derived from hemp occupy a legal gray area. Possession of any amount of marijuana remains a criminal offense, with penalties ranging from Class B misdemeanor to felony depending on quantity.

Ohio

Ohio approved adult-use legalization via Issue 2 in November 2023, with sales launching in August 2024. Daily use increased 38% in the first year of adult sales. The state permits possession of 2.5 ounces for adult use and a 90-day supply for medical patients. Ohio's rapid market growth reflects pent-up demand and an established medical infrastructure that transitioned smoothly to adult use.

Massachusetts

Massachusetts launched adult-use sales in November 2018. Daily users comprise 29% of past-month consumers, with particularly high rates in the 35-54 age bracket. The state permits possession of one ounce in public and up to 10 ounces at home. Massachusetts collects a 10.75% excise tax plus local taxes up to 3%, generating over $200 million in annual cannabis tax revenue.

Market and Business Implications

Daily users drive 75-80% of legal cannabis revenue despite representing only 25-30% of past-month consumers, making this demographic the industry's most critical customer segment. Multi-state operators structure loyalty programs, product development, and retail strategies around daily consumer preferences. These high-frequency customers prioritize value pricing, consistent product availability, and convenient locations. Bulk purchasing discounts, subscription delivery services, and tiered loyalty rewards target this segment. Wholesale pricing has declined significantly as supply expands. Average wholesale flower prices fell from $1,800 per pound in 2020 to $950 per pound in 2025 in mature markets like Colorado and Oregon. Oversupply pressures margins for cultivators while benefiting consumers and retailers. Daily users benefit most from price compression, as their annual spending decreases even as consumption frequency remains stable. Product innovation targets daily users through discreet consumption methods and precise dosing. Vape cartridges, tinctures, and low-dose edibles appeal to consumers seeking functional benefits without intense intoxication. Microdosing—consuming 2-5 mg of THC per dose—has grown rapidly among daily users integrating cannabis into wellness routines. The pending rescheduling to Schedule III would eliminate the 280E tax burden that prohibits cannabis businesses from deducting ordinary business expenses under Internal Revenue Code § 280E. The change could improve operator profitability by 20-40%, according to industry analysts, potentially lowering consumer prices and accelerating market growth. Banking access remains constrained by federal prohibition. The Secure and Fair Enforcement (SAFE) Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has passed the House seven times but stalled in the Senate. Daily users increasingly pay via debit cards and electronic transfers as dispensaries partner with cashless ATM providers and payment processors, though most transactions still occur in cash. Ancillary businesses including real estate, security, compliance software, and testing laboratories benefit from rising daily consumption. The cannabis testing market alone exceeded $1.8 billion in 2025, driven by mandatory potency and contaminant testing in legal states. Daily users prioritize lab-tested products, creating quality assurance demand.

What Experts Say

Public health researchers, industry analysts, and policy advocates offer divergent interpretations of rising daily cannabis use, reflecting broader debates about legalization outcomes. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has emphasized the need for research on daily use effects. According to NIDA communications, Volkow noted that while cannabis is less harmful than tobacco in many respects, daily use carries risks including cognitive effects and dependence that require better understanding and prevention strategies. Dr. Stanton Glantz, tobacco control researcher at the University of California San Francisco, described the cannabis-tobacco crossover as a public health milestone in interviews with medical journals. According to published statements, Glantz said that while cannabis smoke contains carcinogens, the typical consumption pattern of one to three uses per day creates far lower exposure than the 20-cigarette-per-day pattern common among tobacco smokers. Kevin Sabet, president of Smart Approaches to Marijuana, has characterized rising daily use as evidence that commercialization increases problematic consumption. According to SAM press releases, Sabet said that the cannabis industry employs the same playbook as Big Tobacco, targeting heavy users for profit while downplaying addiction risks. Paul Armentano, deputy director of NORML, has argued that increased daily cannabis use reflects substitution rather than net increases in intoxicant consumption. According to NORML testimony before state legislatures, Armentano said that many daily cannabis users are reducing or eliminating alcohol, tobacco, and prescription medications, representing a harm reduction benefit. Dr. Ziva Cooper, director of the UCLA Center for Cannabis and Cannabinoids, has called for research distinguishing between medical and recreational daily use patterns. According to UCLA publications, Cooper said that many daily users consume cannabis to manage chronic pain, insomnia, or anxiety, and that conflating medical necessity with recreational overuse obscures important distinctions. Emily Pera, chief commercial officer at Curaleaf, has described daily users as the foundation of sustainable cannabis retail. According to industry conference presentations, Pera said that operators must balance serving high-frequency customers with responsible retail practices including budtender training, purchase limits, and educational resources.

What's Next: Calendar and Decision Points

The trajectory of daily cannabis use will be shaped by federal rescheduling decisions, state-level legalization expansions, and evolving social norms around cannabis consumption. The DEA's rescheduling decision is expected in late 2026 or early 2027 following the administrative law judge hearing and final review. Rescheduling to Schedule III would maintain federal prohibition on recreational use while acknowledging medical value and reducing tax burdens on operators. The change would not resolve the fundamental federal-state conflict or eliminate criminal penalties for possession. Florida voters will decide Amendment 3 in November 2026. If approved, Florida would become the 25th adult-use state and the first in the Deep South, potentially accelerating legalization in neighboring states including Georgia, Alabama, and South Carolina. Florida's large population and tourist economy would create one of the nation's largest cannabis markets. Pennsylvania, Minnesota, and Ohio legislatures are considering adult-use bills in 2026 sessions. Pennsylvania's House passed legalization legislation in 2023, but the Senate has not acted. Minnesota's divided legislature faces pressure from Governor Tim Walz, who supports legalization. Ohio's successful 2023 ballot initiative may inspire similar campaigns in Missouri, Arkansas, and other states with citizen initiative processes. Federal legislation remains uncertain. The Cannabis Administration and Opportunity Act, introduced by Senate Majority Leader Chuck Schumer, would deschedule cannabis entirely and establish federal taxation and regulation. The bill faces opposition from Republicans and moderate Democrats concerned about youth use and impaired driving. The SAFE Banking Act has broader support but remains stalled. Research infrastructure is expanding. The National Institutes of Health awarded $140 million in grants for cannabis research in 2025, funding studies on daily use patterns, cognitive effects, therapeutic applications, and cannabis use disorder treatment. The University of Mississippi's monopoly on federally legal cannabis cultivation ended in 2021, with additional growers now supplying researchers with chemically diverse samples. Workplace drug testing policies will continue evolving. As more states prohibit employment discrimination based on off-duty cannabis use, employers are adopting impairment-based testing using oral fluid samples that detect recent use rather than metabolites indicating use days or weeks prior. Technology companies are developing breathalyzers and cognitive impairment assessments to replace urinalysis.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• National Survey on Drug Use and Health, Substance Abuse and Mental Health Services Administration — https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health
• Monitoring the Future Survey, National Institute on Drug Abuse — https://nida.nih.gov/research-topics/trends-statistics/monitoring-future
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling, Federal Register Vol. 89, No. 97 (May 2024) — https://www.federalregister.gov
• HHS Recommendation to Reschedule Marijuana, Department of Health and Human Services (August 2023) — https://www.hhs.gov
• State Medical Cannabis Laws, National Conference of State Legislatures — https://www.ncsl.org/health/state-medical-cannabis-laws
• Cannabis Industry Market Data, BDSA Analytics — https://www.bdsa.com
• RAND Corporation Cannabis Policy Research — https://www.rand.org/topics/cannabis.html
• NORML State Laws and Penalties — https://norml.org/laws
• Smart Approaches to Marijuana Policy Positions — https://learnaboutsam.org